Finafloxacin - A Double-blind, Placebo-controlled, Randomised, Dose-escalating, Crossover Study to Determine the Safety and Tolerability of Single and Multiple Intravenous Doses of Finafloxacin in Healthy Subjects

Trial Profile

Finafloxacin - A Double-blind, Placebo-controlled, Randomised, Dose-escalating, Crossover Study to Determine the Safety and Tolerability of Single and Multiple Intravenous Doses of Finafloxacin in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Finafloxacin (Primary)
  • Indications Bacterial infections; Helicobacter infections; Otitis externa; Otitis media; Pyelonephritis; Respiratory tract infections; Urinary tract infections
  • Focus Adverse reactions
  • Sponsors MerLion Pharmaceuticals
  • Most Recent Events

    • 07 Aug 2017 Results published in the Antimicrobial Agents and Chemotherapy
    • 05 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top